Full-Time
Engineering Technician
Updated on 9/3/2026
Mytos
11-50 employees
Automated scalable human cell manufacturing platform
No salary listed
London, UK
In Person
Office-based in London; occasional travel to customer sites domestically and internationally.
 Engineering Management (1) |
|---|
Get referred to Mytos
See people who can refer or advise you
- You're a fast learner and a great communicator who can support the engineering needs of the team and may come from a variety of technical backgrounds.
- You take great pride in a high level of craftsmanship in the work you do.
- You’ve set up new processes & have fabrication experience.
- You have experience of soldering & preparation of cable harnessing to a high level of quality.
- You have excellent IT skills.
- Working alongside our engineering team to assemble/commission new prototypes, our machines & our fluidic consumables.
- Responding to and diagnosing equipment breakdowns / assembly problems, resolving issues and actioning repairs.
- Working closely with our engineering team in finding ways to improve process and increase machine reliability and performance.
- Helping shape our assembly engineering culture and processes so that we keep continually improving. You’ll enjoy the autonomy, accountability and customer-focus that we bring to our work.
- Multi-disciplinary collaboration across the whole team, which includes two Forbes 30 under 30 founders, ex-Dyson engineers, rock climbers and Nature-published scientists
Mytos.bio provides automated, end-to-end manufacturing for human cell types used in biotech. It sells and supports its proprietary Mytos Platform, which combines robotics and software to run cell culture processes without needing more staff. This turns traditional artisanal cell culture into scalable, repeatable production for large biotech firms working on cell therapies and drug development. The system works by integrating automated equipment and software workflows that manage culture, monitoring, and quality control, enabling consistent, high-quality cells at scale. Compared with competitors, Mytos.bio emphasizes a turnkey, scalable infrastructure that reduces headcount while delivering uniform results, backed by a team of hardware and software engineers and biologists, and recognition as a YCombinator alumnus and Forbes 30 Under 30. Its goal is to make large-scale cell production reliable and cost-effective so biopharma companies can accelerate therapies and drug development.
Company Size
11-50
Company Stage
Series A
Total Funding
$20.9M
Headquarters
London, United Kingdom
Founded
2016
Get referred to Mytos
See people who can refer or advise you
Simplify's Take
What believers are saying
- October 2025 CDMO launch targets clinical readiness by September 2026 at CGT Catapult.
- Mytos says the Stevenage site can produce 1,500 autologous or 25,000 allogeneic doses annually.
- November 2025 Aspen raised $115 million Series C, strengthening a major customer relationship.
What critics are saying
- Mytos depends on unproven clinical programs: Aspen, StemSight, Rinri, and Novadip.
- Aspen also partnered with Cell X Technologies in 2025, reducing Mytos' account control.
- If September 2026 CDMO readiness slips, Mytos burns cash before commercial scale.
What makes Mytos unique
- Mytos' iDEM automates hands-off cell manufacturing with fluidics, imaging, and mechanical control.
- September 2025 partnerships with StemSight, Rinri, and Novadip span blindness, deafness, bone repair.
- January 2025 Aspen collaboration embeds Mytos inside a 22,000-square-foot Parkinson's manufacturing facility.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Stock Options
Pension
Lunch covered daily
24 days holiday (excluding bank holidays)
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 4%2 year growth
↑ 0%Mytos announces strategic partnerships with StemSight, Rinri Therapeutics, and Novadip to power next-generation cell therapy trials.
Mytos’ automated cell culture technology will power manufacturing of dopaminergic neuronal precursor cells for Aspen’s investigational cell therapy ANPD001 in Parkinson’s diseaseLONDON–(BUSINESS WIRE)–#automation—Mytos, an innovative leader in automated cell manufacturing, has entered into a manufacturing collaboration with Aspen Neuroscience, Inc. to automate the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs) for ANPD001, Aspen’s investigational cell therapy program for Parkinson’s disease (PD).The DANPCs, designed to replace lost dopamine-producing neurons in the brain, are differentiated from induced pluripotent stem cells (iPSCs), which are derived from the patient’s own skin cells. This approach holds the promise of restoring lost function without the need for immunosuppressive drugs.As part of the partnership agreement, Aspen will integrate Mytos’ iDEM automated cell culture technology into its new manufacturing facility in Torrey Pines, Calif. The iDEM automated cell culture technology combines fluidics, advanced imaging, and mechanical movement and control to enable fully hands-off production of specific human cell types. This agreement represents the potential for substantial payments to Mytos over the coming years.Mytos’ automation has the potential to drive substantial improvements in efficiency and scalability. By closing and automating processes, iDEM empowers operators to manage more batches simultaneously within a smaller cleanroom footprint, minimizing the need for extensive hiring, training, and facility expansions as manufacturing scales out.“We are excited to work with the innovative Mytos team
Generative AI business automation startup Kognitos raised a $20 million Series A led by Khosla Ventures.
Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ Capital and Wing VC.
The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.